Levels of C4d and C4d/C4 associate with clinical and histopathological treatment response in proliferative lupus nephritis. Complement activation markers, particularly C4d and the C4d/C4 ratio, are ...

...in patients with SLE ... E-C4d levels, but not serum C4 levels, were associated with disease activity... Recent evidence suggests that measurement of the erythrocyte-bound complement activation ...

Please provide your email address to receive an email when new articles are posted on . Erythrocyte-bound C4d, a biomarker for systemic lupus erythematosus patented by Exagen Diagnostics, is useful in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FORT WORTH, Texas — In patients with suspected lupus, ...

A complement C4 (also known as a complement component 4, or simply C4) is a test to measure the level of C4 proteins you have in your blood. These proteins play a role in how your immune system ...

Study offers molecular explanation for long-standing observation that certain diseases occur more often or more severely in different sexes. Complement component 4 (C4) genes protect against the ...

Your complement system consists of a group of important proteins in your bloodstream. These proteins help your immune system fight off harmful invaders, such as bacteria, and other foreign substances.

The complement system is part of the body's immune system to fight pathogens and remove cell debris; its role in two autoimmune diseases and a mental disorder is a surprise Variants in a gene of the ...

Most people with lupus have antinuclear antibodies (ANAs) in their blood. But a positive ANA test doesn’t always mean lupus. The test can be positive in people with other autoimmune illnesses — ...

Exagen, a life science company serving the rheumatology specialty, and the Lupus Foundation of America, the national force devoted to solving the mystery of lupus, announced a new initiative to ...

Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.